Futura Medical expects FDA approval for topical ED treatment during Q2

–News Direct–

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder speaks to Proactive's Thomas Warner after announcing the European online launch of topical erectile dysfunction (ED) treatment MED3000, under the brand name Eroxon.

Barder also gives an update on the company's discussions with the FDA regarding MED3000, saying that he expects approval to come during the second quarter.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/futura-medical-expects-fda-approval-for-topical-ed-treatment-during-q2-454503703